Abstract
We describe a case of a 44-year-old man with chronic myeloid leukemia in blastic crisis phase based on peripheral blood smear findings, and the detection of BCR/ABL transcript signals by fluorescence in situ hybridization analysis. Our attempts to quantify the amount of the major BCR/ABL fusion gene revealed that some primers were unable to detect the gene, whereas other primers could detect the gene. We detected a unique deletion on the BCR area by cloning the sequence, which has not been reported previously. Our case suggests that direct sequencing is important when quantitative PCR yields ambiguous results.
This is a preview of subscription content, log in via an institution to check access.
References
Savage DG, Szydlo RM, Goldman JM (1997) Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 96:111–116
Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042
Robert L, Ilaria Jr (2005) Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematol Am Soc Hematol Educ Program 2005:188–194
Hughes TP, Branford S (2009) Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematol Am Soc Hematol Educ Program 2009:477–487
Langabeer SE, Gale RE, Harvey RC, Cook RW, Mackinnon S, Linch DC (2002) Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia 16:393–399
Osumi K, Fukui T, Kiyoi H et al (2002) Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma 43:2291–2299
Estey E, Döhner H (2006) Acute myeloid leukaemia. Lancet 368:1894–1907
Tanaka R, Kimura S, Ashihara E et al (2011) Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Lett 312:228–234
Deininger MW, Goldman JM, Melo JW (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356
Griesshammer M, Heinze B, Bangerter M et al (1997) Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia. J Mol Med 75:836–838
Sherbenou DW, Hantschel O, Kaupe I et al (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116:3278–3285
Zhang JG, Goldman JM, Cross NC (1995) Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. Br J Haematol 90:138–146
Acknowledgments
We would like to thank Mr. Makoto Nagano and Mr. Kenichi Tadokoro from Bio Medical Laboratories for their helpful discussion and technical support.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kunitomi, A., Kimura, S., Okamoto, Y. et al. Myeloid blast crisis in chronic myeloid leukemia with a unique deletion near the BCR/ABL breakpoint. Int Canc Conf J 4, 26–28 (2015). https://doi.org/10.1007/s13691-014-0165-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-014-0165-7